Novelna Inc. is a biotech start-up, pioneering accurate and affordable screening tests for early-stage cancer detection as well as metabolic (NASH) and neurological (MS) disorders. We have two principal pipelines, one blood the other urine-based.
Our core technology rests on a combination of deep proteomics and deep learning approaches; we hold IP for numerous biomarker panels and our platform approach enables us to produce IP-protected tests for other diseases and disorders of interest.
Our core technology rests on a combination of deep proteomics and deep learning approaches; we hold IP for numerous biomarker panels and our platform approach enables us to produce IP-protected tests for other diseases and disorders of interest.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2022
Main Therapeutic Focus:
Diagnostics
Lead Product in Development:
Multiple blood-based cancer diagnostics
Development Phase of Primary Product:
Other/Not Applicable
Number Of Unlicensed Products (For Which You Are Seeking Partners):
10+
Speaker
